ClearPoint Neuro (CLPT) CEO exercises options and holds all shares

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. CEO and President Joseph Burnett exercised stock options to acquire 20,942 shares of Common Stock at $3.24 per share. He paid the exercise price in cash and no shares were sold; all shares received were retained.

Following the exercise, Burnett directly owns 116,842 shares of Common Stock. In addition, 193,231 shares are held indirectly through the Joseph M. Burnett Trust dated 10/20/2022, where he serves as trustee.

Insider Trade Summary

20,942 shares exercised/converted

Mixed 3 txns

Insider BURNETT JOSEPH

Role CEO and President

Type	Security	Shares	Price	Value
Exercise	Stock Options (right to buy)	20,942	$0.00	--
Exercise	Common Stock	20,942	$3.24	$68K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Options (right to buy) — 31,414 shares (Direct); Common Stock — 116,842 shares (Direct); Common Stock — 193,231 shares (Indirect, See footnote)

Footnotes (1)

1. Mr. Burnett paid the exercise price for the options in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. The grant date is July 9, 2020.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURNETT JOSEPH

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/19/2026		M		20,942(1)	A	$3.24	116,842	D
Common Stock								193,231	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$3.24	03/19/2026		M			20,942(1)	(3)	07/09/2030	Common Stock	20,942	$0	31,414	D

Explanation of Responses:

1. Mr. Burnett paid the exercise price for the options in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction.

2. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

3. The shares subject to this option vest as follows: (i) 20% of the total shares on the first anniversary of the grant date; (ii) 40% of the total shares on the second anniversary of the grant date; and (iii) 40% of the total shares on the third anniversary of the grant date. The grant date is July 9, 2020.

	/s/ Danilo D'Alessandro, by Power of Attorney for Joseph M. Burnett	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ClearPoint Neuro (CLPT) CEO Joseph Burnett report in this Form 4?

Joseph Burnett exercised stock options to acquire 20,942 shares of ClearPoint Neuro common stock. He paid the exercise price in cash at $3.24 per share and retained all shares received, with no accompanying stock sales disclosed.

How many ClearPoint Neuro (CLPT) shares does Joseph Burnett own directly after this transaction?

After the option exercise, Joseph Burnett directly owns 116,842 ClearPoint Neuro shares. This figure reflects his direct common stock holdings reported in the Form 4 following the exercise of 20,942 options on March 19, 2026.

Were any ClearPoint Neuro (CLPT) shares sold in connection with this Form 4 transaction?

No shares were sold in connection with this transaction. The footnotes state that Burnett paid the option exercise price in cash and held all shares received, indicating a pure exercise-and-hold event without market sales.

What stock option terms applied to Joseph Burnett’s exercised ClearPoint Neuro (CLPT) options?

The exercised options had an exercise price of $3.24 per share and were granted on July 9, 2020. Footnotes describe a vesting schedule of 20% after one year, then 40% on each of the second and third anniversaries of the grant date.

What indirect ClearPoint Neuro (CLPT) holdings does Joseph Burnett report on this Form 4?

The Form 4 reports 193,231 shares held indirectly through the Joseph M. Burnett Trust dated 10/20/2022. Burnett is trustee of this trust, and these shares are disclosed as indirect common stock ownership separate from his direct holdings.

How many ClearPoint Neuro (CLPT) options did Joseph Burnett exercise in this filing?

Burnett exercised options covering 20,942 shares of ClearPoint Neuro common stock. The derivative line item shows Stock Options (right to buy) for 20,942 underlying shares, which were converted into the same number of common shares on March 19, 2026.